• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Early Safety Study of Atacicept Shows Promise in Rheumatoid Arthritis

Early Safety Study of Atacicept Shows Promise in Rheumatoid Arthritis

January 15, 2008 By Arthritis Center

Atacicept is a recombinant fusion protein that binds and neutralizes two molecules important for the maturation, proliferation, and survival of B cells: BLyS and APRIL.  While B-cell depleting therapies have demonstrated efficacy in RA, atacicept differs from the anti-CD20 targeted monoclonal antibodies, such as rituximab, as its effects extend over the entire lineage of B lymphocytes, including plasma cells.  Here, Tak et al (Arthritis Rheum 2008; 58:61) report early Phase I data on safety and pharmacology of atacicept in RA patients.

Methods

Rheumatoid factor positive RA patients were randomized in a 3:1 fashion to receive atacicept as a single subcutaneous dose of 70, 210, or 630 mg; multiple subcutaneous injections of 70, 210, or 420 mg; or placebo.  Patients were required to have active disease and no history of B cell depleting therapy.  Concomitant therapy with methotrexate (<17.5 mg per week) and prednisone (<10 mg per day) was allowed.  Safety, pharmacokinetic, pharmacodynamic, and preliminary efficacy endpoints were assessed up to three months after the last dose received.  The study was primarily conducted at sites in Russia and Eastern Europe.

Results

73 patients were randomized (18 to placebo and 6 to each of the 6 dosing cohorts).  Women made up 81% of patients with a mean age at enrollment of 56 ± 8 years.  Mean RA duration was approximately 8 years.  On average, patients had active disease, with a mean DAS28 at baseline of 6.6 ± 0.8.

One patient withdrew due to disease worsening.  Five patients discontinued study drug but completed study visits due to the following: generalized urticaria, erythema nodosum, and three for RA worsening or progression.  All five were receiving active study drug.  Overall, 44% of patients reported at least one adverse event, with only 3 events considered serious by pre-defined protocol (arthralgia, RA exacerbation, and rheumatoid nodule).  No serious infections were observed.  One patient had both a worsening of chronic pyelonephritis and an episode of bronchopneumonia occurring 6 and 8 weeks after a single dose of study drug, events of moderate severity and considered possibly related to the study drug.  Four patients developed acute skin symptoms or rash related to administration of study drug, three of whom did not have recurrence on repeated dosing.  Non-serious injection site reactions were observed in 33% of patients.  One death from lung-cancer in a long-time smoker was reported 8 months after receiving study drug.

Four patients had synovial fluid sampling, showing evidence of atacicept and atacicept/BLyS complexes in synovial fluid.  Importantly, decreases in serum immunoglobulins were noted after the first dose of drug and continued through repeated dosing for all IgG subclasses, but most notably for IgM.  Both rheumatoid factor and anti-CCP antibodies were reduced with treatment.  However, atacicept treatment was not associated with decreases in ESR or CRP.  On flow cytometry, all levels of B cells were inhibited, with memory B cells showing the greatest change.  No effect on other lymphocytes or monocytes was noted.
Clinical response data was limited.  Patients in the repeated 420 mg atacicept cohort showed a decrease in mean DAS28 from 6.4 ± 1.3 at baseline to 5.1 ± 1.4 at day 85.

Conclusions

Results of this early Phase 1b study suggest that atacicept is tolerated in the short-term.

Editorial Comment

These results are very preliminary and can only address short-term safety.  However, they are encouraging and suggest that continued study is warranted.  Another anti-BLyS agent, belimumab, has undergone late phase trials in RA.  This agent did not show sufficient efficacy to continue in the pipeline for RA, but is being investigated for use in other rheumatic diseases.  Whether the differences in mechanism between atacicept and belimumab will result in differences in efficacy profiles will require additional study.

The most obvious concern about atacicept is the profound and sustained drop in immunoglobulin levels that over time may result in an increased risk of infection.  Again, further study will help to define whether these are clinically significant.  However, they suggest that the drug may have further applications in diseases, unlike RA, in which pathogenic immunoglobulins are present.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy